

CONFIDENTIAL  
GJS

Dr Laura Green  
Colindale Centre  
NHSBT  
Charcot Road  
London  
NW9 5BG

NHS Blood & Transplant  
c/o National R&D Office  
500 North Bristol Park  
Northway  
Filton  
Bristol  
BS34 7QH

21<sup>st</sup> July 2021

Email: [research.office@nhsbt.nhs.uk](mailto:research.office@nhsbt.nhs.uk)

Dear Laura,

**RE: 21-102-GEN - A randomised controlled trial of pre-hospital whole blood transfusion versus standard care for the resuscitation of patients with life threatening haemorrhage**

I am writing to inform you that you have been awarded £322,294.04 for the above titled project as detailed in the appendix to this letter.

Please be reminded that as a holder of NHSBT research funding, you will be expected to provide annual scientific and financial reports for review by the R&D Committee. These progress reports are an essential part of monitoring the effectiveness of investment in R&D and must be submitted on time. If there are any significant delays or issues with this work, please inform the R&D Office immediately to ensure that steps can be taken to manage these.

If you have any questions relating to this grant (Reference Number **21-102-GEN**) please contact the NHSBT R&D Office ([research.office@nhsbt.nhs.uk](mailto:research.office@nhsbt.nhs.uk)) who will be happy to deal with your enquiry.

Yours sincerely

NHS Blood and Transplant Research and Development Office

cc: R&D Office, NHSBT  
Mina Chauhan, Finance Business Partner (R&D, Clinical and SCDT), NHSBT  
Rachel Johnson, Assistant Director - Statistics and Clinical Research

Appendix – Budget Table

| COST CATEGORY TOTAL                               | REVENUE COSTS WITHIN THE PERIOD |                     |                     |                     | TOTAL             |
|---------------------------------------------------|---------------------------------|---------------------|---------------------|---------------------|-------------------|
|                                                   | APR 2021 - MAR 2022             | APR 2022 - MAR 2023 | APR 2023 - MAR 2024 | APR 2024 - MAR 2025 |                   |
| <b>SALARY</b>                                     | 25,751.24                       | 46,004.00           | 96,989.35           | 41,311.25           | 210,055.84        |
| <b>INFORMATION TECHNOLOGY COSTS</b>               | 0.00                            | 0.00                | 0.00                | 0.00                | 0.00              |
| <b>TRAVEL &amp; SUBSISTENCE</b>                   | 2,200.00                        | 2,850.00            | 5,730.00            | 650.00              | 11,430.00         |
| <b>TRAINING &amp; CONFERENCES</b>                 | 0.00                            | 0.00                | 0.00                | 4,000.00            | 4,000.00          |
| <b>CONSUMABLES, CHEMICALS &amp; REAGENTS</b>      | 0.00                            | 47,074.10           | 47,434.10           | 2,300.00            | 96,808.20         |
| <b>EQUIPMENT PURCHASE, HIRE &amp; MAINTENANCE</b> | 0.00                            | 0.00                | 0.00                | 0.00                | 0.00              |
| <b>DEPRECIATION</b>                               | 0.00                            | 0.00                | 0.00                | 0.00                | 0.00              |
| <b>TOTAL COST</b>                                 | <b>27,951.24</b>                | <b>95,928.10</b>    | <b>150,153.45</b>   | <b>48,261.25</b>    | <b>322,294.04</b> |